IMA203 + nivolumab plus relatlimab + lifileucel + nivolumab + pembrolizumab + ipilimumab + Dacarbazine + temozolomide + paclitaxel + paclitaxel plus carboplatin + Albumin-Bound Paclitaxel

Phase 3Recruiting

1 views this week 0 watching⚡ Active

Interest: 41/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Melanoma, Cutaneous Malignant

Conditions

Melanoma, Cutaneous Malignant

Trial Timeline

Jan 14, 2025 → Oct 1, 2031

NCT ID

NCT06743126

About IMA203 + nivolumab plus relatlimab + lifileucel + nivolumab + pembrolizumab + ipilimumab + Dacarbazine + temozolomide + paclitaxel + paclitaxel plus carboplatin + Albumin-Bound Paclitaxel

IMA203 + nivolumab plus relatlimab + lifileucel + nivolumab + pembrolizumab + ipilimumab + Dacarbazine + temozolomide + paclitaxel + paclitaxel plus carboplatin + Albumin-Bound Paclitaxel is a phase 3 stage product being developed by Immatics for Melanoma, Cutaneous Malignant. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06743126. Target conditions include Melanoma, Cutaneous Malignant.

What happened to similar drugs?

4 of 20 similar drugs in Melanoma, Cutaneous Malignant were approved

Approved (4) Terminated (2) Active (14)

✅dabrafenib + trametinibNovartisApproved

✅ZelborafRocheApproved

✅Nivolumab + RelatlimabBristol Myers SquibbApproved

✅Fibrin Sealant (Tisseel) used in the Experimental Arm.BaxterApproved

❌Tasisulam-sodium + PaclitaxelEli LillyPhase 3

🔄Pembrolizumab + Lenvatinib + Placebo for lenvatinibEisaiPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06743126	Phase 3	Recruiting	Jan 14, 2025	Oct 1, 2031	Melanoma, Cutaneous Malignant

Competing Products

20 competing products in Melanoma, Cutaneous Malignant

See all competitors

Product	Company	Stage	Hype Score
mRNA-4157 + Pembrolizumab	Merck	Phase 2	39
AVT32-DRL_PB + Keytruda	Dr. Reddy's Laboratories	Phase 1	33
Binimetinib Oral Tablet	Biotrial	Phase 1	15
Tasisulam-sodium + Paclitaxel	Eli Lilly	Phase 3	32
[203Pb]VMT01 + [212Pb]VMT01 + Nivolumab	Perspective Therapeutics	Phase 1/2	33
[203Pb]VMT01 + [68Ga]VMT02	Perspective Therapeutics	Phase 1	23
FYB206 + Keytruda	Formycon AG	Phase 1	23
PLX3397	Daiichi Sankyo	Pre-clinical	26
PLX3397 + Pembrolizumab	Daiichi Sankyo	Phase 1/2	24
Trastuzumab deruxtecan	Daiichi Sankyo	Phase 2	39
DS-8273a + Nivolumab	Daiichi Sankyo	Phase 1	29
PLX3397 + vemurafenib	Daiichi Sankyo	Phase 1	21
enfortumab vedotin + pembrolizumab	Astellas Pharma	Phase 2	42
CP-461	Astellas Pharma	Phase 2	27
YM155	Astellas Pharma	Phase 2	35
YM155 + Docetaxel	Astellas Pharma	Phase 2	35
Denileukin diftitox	Eisai	Phase 2	35
E7080	Eisai	Phase 1	29
lenvatinib + pembrolizumab	Eisai	Phase 2	35
MORAb-004 (monoclonal antibody)	Eisai	Phase 2	35